UK markets closed
NIKKEI 225
38,471.20 -761.60 (-1.94%) HANG SENG
16,248.97 -351.49 (-2.12%) CRUDE OIL
85.30 -0.11 (-0.13%) GOLD FUTURES
2,404.60 +21.60 (+0.91%) DOW
37,798.97 +63.86 (+0.17%) Bitcoin GBP
50,654.41 -335.39 (-0.66%)
AstraZeneca PLC (AZN.L)
LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
At close: 04:39PM BST
| Previous close | 11,024.00 |
| Open | 10,882.00 |
| Bid | 10,500.00 x 0 |
| Ask | 11,380.00 x 0 |
| Day's range | 10,822.00 - 10,966.00 |
| 52-week range | 9,461.00 - 12,392.00 |
| Volume | |
| Avg. volume | 2,951,318 |
| Market cap | 168.634B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 35.67 |
| EPS (TTM) | 3.05 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | 2.28 (2.07%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | 125.30 |
Business WireIMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).
ZacksAstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.
ZacksPharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.
© 2024 Yahoo. All rights reserved.